Patient Groups in British Columbia Criticize Mandatory Switch to Biosimilars in IBD

Patient Groups in British Columbia Criticize Mandatory Switch to Biosimilars in IBD
A collaboration of Canadian patient organizations said British Columbia’s (BC) decision to switch those with inflammatory bowel disease (IBD) to biosimilar drugs is short-sighted and a breach of conventional patient-physician boundaries. The Biosimilars Working Group advises the 1,700 Crohn’s disease and ulcerative colitis patients affected by the change to consult with their physicians before changing from Remicade (infliximab) to Inflectra (infliximab-dyyb) or Renflexis (infliximab-abda). Under the province’s Biosimilars Initiative, patients have about six months to transition to the new drugs. After March 5, the publicly funded coverage program
Subscribe or to access all post and page content.